Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma

Journal of the American Academy of Dermatology

Volumn 67, Issue 6, 2012, Pages 1375-1379

  Boyd, Kevin P ^a   Vincent, Bethaney ^a   Andea, Aleodor ^a   Conry, R Martin ^a   Hughey, Lauren C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

BRAF; drug reaction; follicular hyperkeratosis; metastatic melanoma; retinoids; vemurafenib

Indexed keywords

AMMONIUM LACTATE; CAPECITABINE; CYTARABINE; DABRAFENIB; ETRETIN; KERATOLYTIC AGENT; LIDOCAINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PREGABALIN; RETINOID; SALICYLIC ACID; SORAFENIB; STEROID; TRAMETINIB; UREA; VEMURAFENIB;

ACNE; ALOPECIA; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONSERVATIVE TREATMENT; DARIER DISEASE; DRUG WITHDRAWAL; DYSKERATOSIS; ERYTHEMA; HAIR DISEASE; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; HYPERKERATOSIS; KERATINOCYTE; KERATOACANTHOMA; LOW DRUG DOSE; METASTATIC MELANOMA; NON MELANOMA SKIN CANCER; PAIN; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; SEBORRHEIC DERMATITIS; SKIN CARCINOMA; SKIN CYST; SKIN MANIFESTATION; SKIN PAPILLOMA; SPINY FOLLICULAR HYPERKERATOSIS; TOPICAL TREATMENT; XEROSIS;

EID: 84869099704     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.06.045     Document Type: Review

References (24)

1. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
2. A. Platz, S. Egyhazi, U. Ringborg, and J. Hansson Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site Mol Oncol 1 2008 395 405
3. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
4. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
5. R. Kefford, H. Arkenau, M.P. Brown, M. Millward, J.R. Infante, and G.V. Long Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract 8509] J Clin Oncol 2010 28(Suppl):15S
6. A. Ribas, K.B. Kim, L.M. Schuchter, R. Gonzalez, A.C. Pavlick, and J.S. Weber BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation positive metastatic melanoma [abstract] J Clin Oncol 2011 29(Suppl):ABST8509
7. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, and J.S. Weber Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
8. P.A. Oberholzer, D. Kee, P. Dziunycz, A. Sucker, N. Kamsukom, and R. Jones RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors J Clin Oncol 30 2012 316 321
9. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, and O. Spleiss RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 366 2012 207 215
10. V. Huang, D. Hepper, M. Anadkat, and L. Cornelius Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway Arch Dermatol Published online March 19, 2012
11. J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor Arch Dermatol 144 2008 886 892
12. N. Franck, S. Barete, P. Moguelet, B. Blanchet, A. Carlotti, and S. Ropert Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib J Clin Oncol 28 2010 e640 e642
13. S. Sahai, and B.L. Swick Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib Int J Dermatol 49 2010 1203 1206
14. C.H. Yang, W.C. Lin, C.K. Chuang, Y.C. Chang, S.T. Pang, and Y.C. Lin Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy Br J Dermatol 158 2008 592 596
15. W.J. Lee, J.L. Lee, S.E. Change, M.W. Lee, Y.K. Kang, and J.H. Choi Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib Br J Dermatol 161 2009 1045 1051
16. H.H. Kong, and M.L. Turner Array of cutaneous adverse effects associated with sorafenib J Am Acad Dermatol 61 2009 360 361
17. E.J. Kwon, L.S. Kis, and C. Jaworsky The histologic spectrum of epithelial neoplasms induced by sorafenib J Am Acad Dermatol 61 2009 522 527
18. M.E. Lacouture, S. Wu, C. Robert, M.B. Atkins, H.H. Kong, and J. Guitart Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib Oncologist 13 2008 1001 1011
19. C. Robert, C. Mateus, A. Spatz, J. Wechsler, and B. Escudier Dermatologic symptoms associated with the multikinase inhibitor sorafenib J Am Acad Dermatol 60 2009 299 305
20. M.H. Nissan, and D.B. Solit The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors, or both? Curr Oncol Rep 13 2011 479 487
21. Hoffmann-La Roche. A study of RO5185426 And GDC-0973 in patients with BRAF-mutation positive metastatic melanoma. Available from: URL: http://www.clinicaltrials.gov/ct2/show/NCT01271803. Accessed February 4, 2012.
22. J.R. Infante, G.S. Falchook, D.P. Lawrence, J.S. Weber, R.F. Kefford, and J.C. Bendell Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract] J Clin Oncol 29 Suppl 2011 ABSTCRA8503
23. C. Marquez, S.M. Bair, E. Smithberger, B.S. Cherpelis, and L.F. Glass Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients J Drugs Dermatol 9 2010 753 758
24. S.B. Cheepala, W. Yin, Z. Syed, J.N. Gill, A. McMillian, and H.E. Kleiner Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion Mol Cancer 8 2009 27